Combination therapy comprising cloretazine

Details Combination therapy comprising cloretazine Combination therapy comprising cloretazine

2005-03-25

2009-10-20

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S045000, C514S046000, C514S050000, C514S086000, C514S274000, C564S035000

Reexamination Certificate

active

07605137

ABSTRACT:
This invention provides a method for treating tumor in a subject comprising administering to the subject an effective amount of: (1) VNP40101M, or its equivalent; and (2) a nucleoside, or a nucleoside analog. This invention also provides a method for inhibiting tumor cell growth comprising contacting the tumor cell with effective amounts of: (1) VNP40101M, or its equivalent; and (2) a nucleoside, or a nucleoside analog. The present invention relates to the treatment of cancer, comprising administering to a subject in need thereof an effective amount of VNP40101M in combination with a nucleoside.

REFERENCES:
patent: 4175200 (1979-11-01), Hunter et al.
patent: 4385055 (1983-05-01), Klayman et al.
patent: 4447427 (1984-05-01), Klayman et al.
patent: 4684747 (1987-08-01), Satorelli et al.
patent: 4696938 (1987-09-01), Le
patent: 4849563 (1989-07-01), Satorelli et al.
patent: 5101072 (1992-03-01), Satorelli et al.
patent: 5214068 (1993-05-01), Satorelli et al.
patent: 5256820 (1993-10-01), Satorelli et al.
patent: 5637619 (1997-06-01), Satorelli et al.
patent: 5767134 (1998-06-01), Li et al.
patent: 5919816 (1999-07-01), Hausheer et al.
patent: 6040338 (2000-03-01), Satorelli et al.
patent: 6630480 (2003-10-01), Gourdeau et al.
patent: 6696487 (2004-02-01), Gerusz et al.
patent: 6855695 (2005-02-01), Lin et al.
patent: 2005/0043244 (2005-02-01), Lin et al.
patent: 101014353 (2007-08-01), None
patent: 1804816 (2007-07-01), None
patent: 1107775 (2008-04-01), None
patent: WO/02/30424 (2002-04-01), None
patent: WO 2005/094282 (2005-10-01), None
Lee et al, International Journal of Toxicology, 2002, 21, 23-38.
Baumann RP, et al., 2004, “1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkytransferase in cytotoxicity.” Cancer Chemother Pharmacol. 53(4):288-295.
Burchenal, et al., 1988, “Cancer: the Outlaw Cell,” ed. Richard E Lafond, American Chemical Society: 204-205.
Gura, et al., 1997, “Systems for identifying new drugs are often faulty,” Science: 278(5340):1041-2.
Lee, et al., 2002, “Toxicological evaluation of 1,2 bis(methylsulfonyl)-1-(2-chloroethyl)-2(methylaminocarbonyl) hydrazine (VNP40101M), novel alkylating Agent with Potential Antitumor Activity, with Intravenous Administration in Rats and Dogs”, Interntional Journal of Toxicology. vol. 23: 23-39.
Hrubiec, et al., 1986, “Synthesis and evaluation of 1 -(arylsulfonyl)-2-[(methoxycarbonyl)sulfenyl]-1 methylhydrazines ++ + as antineoplastic agents.” J Med Chem. 29(9):1777-9.
Hrubiec, et al., 1986, “Synthesis and evaluation of 2-substituted 1-methyl-1-(4-tolysulfonyl)hydrazines as antineoplastic agents,” J Med Chem. 29(7):1299-301.
Murren, et al., 2005, “A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer”, Investigational New Drugs. vol. 23: 123-135.
Mao, et al., 2002, “Pharmacokinetics, Mass Balance, and Tissue Distribution of a Novel DNA Alkylating Agent, VNP40101M, in Rats”, AAPS PharmSci: 4(4)24.
Penketh, et al., 1994, “Studies on the mechanism of decomposition and structural factors affecting the aqueous stability of 1,2-bis(sulfonyl)-1-alkylhydrazines”, J Med Chem 37: 2912-2917.
Penketh, et al., 2000, “Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas”, Biochem Pharmacol 59:283-91.
Pratviel, et al., 1989, “Cytotoxic and DNA-damaging Effects of 1,2-bis(sulfonyl)hydrazines on Human Cells of the Mer+ and Mer− phenotype”, Cancer Biochem Biophys 10:365-75 (abstract only).
Shyam, et al., 1985, “Synthesis and evaluation of N,N′-bis(arylsulfonyl)hydrazines as antineoplastic agents” J Med Chem 28:525-7.
Shyam, et al., 1986, “1,2-bis(arylsulfonyl)hydrazines. 2. The influence of arylsulfonyl and aralkylsulfonyl substituents on antitumor and alkylating activity”, J Med Chem 29:1323-5.
Shyam, et al., 1987, “1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity”, J Med Chem 30:2157-61.
Shyam, et al., 1990, “Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents”, J Med Chem 33(8):2259-64.
Shyam, et al., 1993, “Synthesis and evaluation of 1-acyl-1,2-bis(methylsulfonyl)-2-(2- chloroethyl)hydrazines as antineoplastic agents”, J Med Chem 36:3496-502.
Shyam, et al., 1996, Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)- hydrazines, J Med Chem 39:796-801.
Giles, et al., 2004, “A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia.”, Clinical Cancer Research, vol. 10, pp. 2908-2917.
Ishiguro, et al., 2005, “Role of 0-alkylguanine-DNA alkyltransferase in the cytotoxic activity of clorezatine”, Mol Cancer Ther, vol. 4 (11), pp. 1755-1763.
Rice, et al., 2005, “Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU.” , Biochemical Pharmacology, vol. 69, pp. 1463-1472.
PCT International Search Report for VION Pharmaceuticals, et al., Int'l Application No. PCT/US2005/010152, filed Mar. 25, 2005, Dated Mar. 21, 2006.
Lee, et al., “Toxicological evaluation of 1,2 bis(methylsulfonyl)-1-(2-chloroethyl)-2 (methylaminocarbonyl) hydrazine (VNP40101M), novel alkylating Agent with Potential Antitumor Activity, with Intravenous Administration in Rats and Dogs”., International Journal of Toxicology, vol. 23, pp. 23-29 (2002).
Ishiguro, et al., “Role of 0-alkylguanine-DNA alkyltransferase in the cytotoxic activity of clorezatine”, Mol Cancer Ther, vol. 4 (11), pp. 1755-1763 (2005).
Murren, et al., “A phase I and pharmacokinetic study of VNP4010M, a new alkylating agent, in patients with advanced or metastatic cancer”., Investigational New Drugs, vol. 23, pp. 123-135 (2005).
Giles, et al., “A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia.”, Clinical Cancer Research, vol. 10, pp. 2908-2917 (2004).
Rice, et al., “Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU.”, Biochemical Pharmacology, vol. 69, pp. 1463-1472 (2005).
PCT International Preliminary Report on Patentability for VION Pharmaceuticals, et al., Int'l Application No. PCT/US2005/010152. Filed Mar. 25, 2005, Dated Sep. 26, 2006.
International Search Report issued Mar. 21, 2006 for Vion Pharmaceuticals, Inc, et al., International Publication No. WO/2005/094282.
Written Opinion of the International Searching Authority, issued Mar. 21, 2006 for Vion Pharmaceuticals, Inc, et al., International Publication No. WO/2005/094282.
Penketh, et al., 1986, “Mechanisms of resistance to alkylating agent”, Cancer Treat Res 87:65-81.
U.S. Appl. No. 60/556,565, filed Mar. 26, 2004, King et al.
Finch et al., Apr. 1, 2001, “1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): A Novel Sulfonylhydrazine Prodrug with Broad-Spectrum, Antineoplastic Activity”, Cancer Research, vol. 61(7):3033-3038.

Affiliated with

Also associated with

Rating

Combination therapy comprising cloretazine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination therapy comprising cloretazine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy comprising cloretazine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4143000